TABLE 1

Biodistribution of ¹⁸F-FDG After Treatment

	24 h after treatment			48 h after treatment
Tissue	Saline-treated	Doxorubicin-treated	P	Saline-treated	Doxorubicin-treated	P
Cerebellum	2.83 ± 0.13	2.46 ± 0.40	NS	2.84 ± 0.43	2.93 ± 0.51	NS
Cerebral cortex	2.61 ± 0.29	2.14 ± 0.28	<0.05	2.86 ± 0.39	2.32 ± 0.53	NS
Rest of brain	2.26 ± 0.37	1.82 ± 0.25	0.06	2.33 ± 0.30	2.34 ± 0.32	NS
Adipose tissue	0.20 ± 0.08	0.44 ± 0.16	<0.05	0.15 ± 0.08	0.48 ± 0.06	<0.0001
Bladder	4.17 ± 1.14	2.79 ± 2.15	NS	3.98 ± 1.31	3.87 ± 1.05	NS
Bone	0.38 ± 0.07	0.33 ± 0.12	NS	0.32 ± 0.09	0.36 ± 0.09	NS
Bone marrow	1.10 ± 0.22	1.04 ± 0.14	NS	0.98 ± 0.12	1.26 ± 0.24	0.06
Heart	9.84 ± 2.63	8.69 ± 3.91	NS	9.86 ± 3.28	10.7 ± 3.28	NS
Large intestine	1.72 ± 0.23	2.69 ± 0.58	<0.02	1.75 ± 0.21	2.92 ± 0.54	<0.01
Small intestine	1.59 ± 0.14	2.03 ± 0.51	NS	2.01 ± 0.63	3.15 ± 0.73	<0.05
Kidney	1.74 ± 0.57	1.94 ± 0.48	NS	1.43 ± 0.24	1.97 ± 0.47	0.06
Liver	0.95 ± 0.17	1.01 ± 0.22	NS	1.04 ± 0.17	1.03 ± 0.15	NS
Lung	1.23 ± 0.12	1.25 ± 0.19	NS	1.38 ± 0.18	1.23 ± 0.12	NS
Muscle	0.19 ± 0.03	0.22 ± 0.05	NS	0.22 ± 0.04	0.18 ± 0.05	NS
Pancreas	0.49 ± 0.12	0.55 ± 0.13	NS	0.50 ± 0.10	0.82 ± 0.10	0.002
Plasma	0.97 ± 0.22	1.25 ± 0.44	NS	1.00 ± 0.28	1.17 ± 0.18	NS
Red blood cells	0.64 ± 0.13	0.66 ± 0.10	NS	0.73 ± 0.15	0.75 ± 0.10	NS
Spleen	1.63 ± 0.10	1.47 ± 0.19	NS	1.63 ± 0.20	1.62 ± 0.17	NS
Submandibular gland	1.32 ± 0.18	1.12 ± 0.30	NS	1.32 ± 0.12	0.98 ± 0.19	<0.02
Tumor	5.71 ± 1.44	4.21 ± 1.30	NS^*	6.26 ± 0.71	4.33 ± 0.84	<0.01

↵* Not significant in 2-sample t test because of large differences in ¹⁸F-FDG uptake between individual rats, but statistically significant (P < 0.01) in paired t test (saline- vs. doxorubicin-treated rat studied on same day).
NS = not statistically significant.
Data are mean standardized uptake values (±SD).